Sonidegib: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
HAS (France), NYE METODER (Norway) and PBAC (Australia) recommended or restricted sonidegib, while AWMSG (Wales) and TLV (Sweden) did not recommend it.
Assessment has run over 10 years, from 10 Dec 2015 at AWMSG (Wales) to 17 Dec 2025 at DMC (Denmark).
No assessment is on file from SMC (Scotland), PHARMAC (New Zealand) and CIPM (Spain), each among the eight highest-volume agencies here.
The file is active: 3 of 9 records date from 2023 or later.
Against its own class, sonidegib is an outlier: 50% of its decisive outcomes were positive, where molecules sharing ATC class L01X average 75%.
3 distinct indication wordings are recorded for sonidegib by the agencies that label one in English (AWMSG and PBAC).
2 of these 9 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess sonidegib, on 10 Dec 2015; DMC (Denmark) did not open a file until 17 Dec 2025 — an unusually long tail of 10 years between the earliest and latest system to look at it.
2 of the 7 agencies here assessed sonidegib more than once, TLV (Sweden) most often at 2 entries — repeat review is the norm for this molecule rather than the exception.
7 of the 18 agencies in this archive hold a record for sonidegib.
The full ledger for sonidegib reads 3 not recommended, 3 recommended, 1 other and 1 advice, with 1 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| PBAC (Australia) | 2023 | Metastatic or locally advanced basal cell carcinoma (BCC) | Advice Provided | source |
| TLV (Sweden) | 19 May 2023 | Odomzo ingår inte i högkostnadsskyddet | rejection or exclusion | source |
| NYE METODER (Norway) | 29 Aug 2021 | Behandling av lokalavansert basalcellekarsinom hos voksne som har tilbakefall etter kirurgi eller stråling eller som ikk… | introduced | source |
| G-BA (Germany) | 2 Aug 2018 | Odomzo — benefit assessment §35a | added benefit: not proven | source |
| HAS (France) | 8 Jun 2016 | Listing (Transparency Committee) | SMR substantial · ASMR IV | source |
4 further decisions for sonidegib, across 4 agencies, are not shown here. They include the most recent record on file, 17 Dec 2025 from DMC (Denmark); its outcome is in the subscriber dataset. They link to 3 further source documents.
Related molecules
- atezolizumab — same ATC class L01X — Antineoplastics
- olaparib — same ATC class L01X — Antineoplastics
- durvalumab — same ATC class L01X — Antineoplastics
- aflibercept — same ATC class L01X — Antineoplastics
- osimertinib — same ATC class L01X — Antineoplastics
- venetoclax — same ATC class L01X — Antineoplastics
Coverage: 9 decisions for sonidegib from 7 agencies, 2015 to 2025. Data to 7 Sep 2026. ATC class L01X — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.